Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers.

Lucy Marie CarterZoe WigstonPhilip LawsEdward M Vital

Published in: The British journal of dermatology (2023)

These data indicate rapid efficacy of anifrolumab in DLE and rituximab-resistant CLE. Response is associated with suppression of a subset of ISGs and decline in intermediate monocytes. Suppression of all ISGs or the wider SLE blood transcriptome is not required for response.

Keyphrases

systemic lupus erythematosus
single cell
rna seq
disease activity
peripheral blood
gene expression
loop mediated isothermal amplification
electronic health record
genome wide
dendritic cells
dna methylation
immune response
quantum dots